CD44 and neoplasm: Engineering tumor‐colonizing Escherichia coli Nissle 1917 targeted explicitly to tumor‐targeting adhesion protein heparan sulfate proteoglycan could result in >95% proliferation inhibition of CRC cells and reduce CRC adenoma burden by ~50% in vivo [16].